EGFR and neoplasm: The diagnostic sensitivity of these techniques, when compared to tumor tissue, ranges from 43 to more than 90%, while the specificity is usually close to 100%; and the two commercially available methods to determine EGFR mutations in the cfDNA of cancer patients (Therascreen Plasma from Qiagen and COBAS Blood from Roche Diagnostics) are based on them.